Navigation Links
X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD

WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong).

Under the terms of the collaboration, Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts, for the Greater China markets.  X-BODY retains all development and commercialization rights outside of Greater China.  Detailed financial terms were not disclosed, but terms of the alliance include an upfront payment; clinical, regulatory and commercialization milestones; and royalties on revenues from commercialized products.

"It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY," said Lianshan Zhang, Ph.D., President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.

"This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform.  We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients' lives, especially for a disease as life-altering as AMD," added Julius Knowles , CEO of X-BODY.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual R&D investment of over US$ 100 million. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with dozens of new molecular entities in clinical trials and under preclinical development.  Hengrui's products and R&D span over multiple therapeutic areas, such as oncology-hematology, anesthesiology, cardiovascular and metabolic diseases, ophthalmology, and inflammation. For more information, please visit and

About X-BODY Biosciences

X-BODY creates therapeutic antibodies against the most challenging and high-value drug targets, and is primarily focused on integral membrane proteins, such as GPCRs, ion channels, and transporters.  X-BODY is collaborating with leading biotech and pharmaceutical companies to progress its platform and its compounds.  X-BODY also generates antibodies internally, and has programs focused in oncology, ophthalmology, and metabolic diseases.  X-BODY is headquartered in Waltham, MA. For more information, please visit

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argon Medical Devices Announces The Launch Of OptionELITE Retrievable Vena Cava Filter And The Acquisition of Angiotech Interventional Business
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. Akorn, Inc. Announces First Quarter 2013 Earnings Release And Conference Call Information
4. Dynamic Healthcare Services Announces David Erb as Director of Sales
5. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
6. Organovo Holdings, Inc. Announces Change of Fiscal Year
7. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
8. China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to Satisfy Continued Listing Letter
9. MD+DI Announces 46 Innovative Products as Finalists in 2013 Medical Design Excellence Awards
10. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the First Quarter Ended March 31, 2013
11. Research and Markets Announces the Release of Cellulose Ethers Market By Derivative & Application - Global Trends & Forecasts to 2017
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):